VSTM logo

VSTM
Verastem Inc

24,070
Mkt Cap
$362.92M
Volume
2.15M
52W High
$11.25
52W Low
$4.01
PE Ratio
-1.51
VSTM Fundamentals
Price
$4.31
Prev Close
$4.13
Open
$4.07
50D MA
$5.48
Beta
1.38
Avg. Volume
1.99M
EPS (Annual)
-$3.02
P/B
4.44
Rev/Employee
$303,078.43
$417.24
Loading...
Loading...
News
all
press releases
Cancer Stocks That Are Advancing the Future of Oncology Care
Oncology innovation is accelerating as AI, immunotherapy and targeted drugs drive growth for cancer-focused biotech and pharma stocks.
Zacks·3d ago
News Placeholder
More News
News Placeholder
Verastem (VSTM) Loses 34.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Verastem (VSTM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks·3d ago
News Placeholder
Verastem Oncology to Present at Upcoming Investor Conferences
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is...
Business Wire·9d ago
News Placeholder
On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer
Today, STAAR Low-Grade Serous Ovarian Cancer Foundation, Not These Ovaries, and Verastem Oncology announced the launch of the LGSOC Resource Guide, a unique resource designed to support patients...
Business Wire·13d ago
News Placeholder
Verastem (VSTM) Reports Q1 Loss, Misses Revenue Estimates
Verastem (VSTM) delivered earnings and revenue surprises of 0.00% and -16.09%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·14d ago
News Placeholder
Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported financial results for the first...
Business Wire·14d ago
News Placeholder
Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI FAKZYNJA CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the launch of its Reimagine...
Business Wire·21d ago
News Placeholder
Verastem (VSTM) Projected to Post Earnings on Thursday
Verastem (NASDAQ:VSTM) will be releasing its Q1 2026 earnings after the market closes on Thursday, May 7. (View Earnings Report at...
MarketBeat·21d ago
News Placeholder
Verastem, Inc. (NASDAQ:VSTM) Receives Average Rating of "Moderate Buy" from Analysts
Verastem, Inc. (NASDAQ:VSTM - Get Free Report) has been given an average rating of "Moderate Buy" by the nine brokerages that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, five have assigned a bu...
MarketBeat·28d ago
News Placeholder
Torray Investment Partners LLC Purchases Shares of 216,387 Verastem, Inc. $VSTM
Torray Investment Partners LLC purchased a new stake in shares of Verastem, Inc. (NASDAQ:VSTM - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange...
MarketBeat·28d ago
<
1
2
...
>

Latest VSTM News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.